New CGM algorithm could simplify insulin dosing for diabetes
NCT ID NCT06111508
First seen Mar 08, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This pilot study tested a new algorithm that uses continuous glucose monitor (CGM) data to automatically adjust long-acting insulin doses in people with type 2 diabetes. Thirty participants were followed for 18 weeks to see if the algorithm improved blood sugar control compared to standard self-monitoring. The goal was to increase the time blood sugar stays in a healthy range without causing dangerous lows.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Degludec insulin (long-acting insulin) and a continuous glucose monitor (CGM)-based titration algorithm
What this could lead to
If successful, this could lead to a simpler, more effective way for people with type 2 diabetes to manage their insulin doses using continuous glucose monitoring.
What could go wrong
This is a small, early pilot study with only 30 participants, so results may not apply to everyone. The algorithm may not improve blood sugar control significantly or could cause low blood sugar events.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.